Literature DB >> 12687635

Fluoxetine depresses glutamate exocytosis in the rat cerebrocortical nerve terminals (synaptosomes) via inhibition of P/Q-type Ca2+ channels.

Su-Jane Wang1, Chin-Feng Su, Yu-Heng Kuo.   

Abstract

Fluoxetine, an antidepressant that is used clinically in the treatment of mood disorders, is a selective serotonin reuptake inhibitor. In the present study we investigated the effects of fluoxetine on 4-aminopyridine (4AP)-evoked glutamate release in cerebrocortical nerve terminals (synaptosomes). Fluoxetine suppressed the release of glutamate evoked by 4AP in a concentration-dependent manner. This effect was associated with a reduction in the depolarization-evoked increase in cytosolic free calcium levels in the absence of significant effect on the synaptosomal membrane potential. In addition, both ionomycin- and sucrose-evoked glutamate releases were not affected by fluoxetine, indicating that fluoxetine-mediated inhibition of glutamate release is not a direct effect on the exocytotic machinery. Furthermore, the inhibitory action of fluoxetine was completely abolished in synaptosomes pretreated with P/Q type Ca(2+) channel blocker omega-agatoxin IVA (omega-AgTX IVA) or protein kinase C (PKC) stimulator 4beta-phorbol 12, 13-dibutyrate (PDBu). These results suggest that, in cerebrocortical nerve terminals, fluoxetine inhibits glutamate release through the suppression of P/Q type Ca(2+) channel activity. The presynaptic action of fluoxetine is mediated by a PKC-sensitive signaling pathway. Synapse 48:170-177, 2003. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12687635     DOI: 10.1002/syn.10200

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  14 in total

1.  Improvement in depressive symptoms with felbamate: a case report.

Authors:  Ashish Sharma; Jamie Drake; Mahliqha Qasimyar; Suzanne Tucker
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

Review 2.  Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.

Authors:  Gerard Sanacora; Giulia Treccani; Maurizio Popoli
Journal:  Neuropharmacology       Date:  2011-08-03       Impact factor: 5.250

3.  Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus.

Authors:  Giambattista Bonanno; Roberto Giambelli; Luca Raiteri; Ettore Tiraboschi; Simona Zappettini; Laura Musazzi; Maurizio Raiteri; Giorgio Racagni; Maurizio Popoli
Journal:  J Neurosci       Date:  2005-03-30       Impact factor: 6.167

4.  Serotonin Depletion Does not Modify the Short-Term Brain Hypometabolism and Hippocampal Neurodegeneration Induced by the Lithium-Pilocarpine Model of Status Epilepticus in Rats.

Authors:  Luis García-García; Ahmed Anis Shiha; Pablo Bascuñana; Javier de Cristóbal; Rubén Fernández de la Rosa; Mercedes Delgado; Miguel A Pozo
Journal:  Cell Mol Neurobiol       Date:  2015-07-25       Impact factor: 5.046

Review 5.  Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?

Authors:  Pal Pacher; Valeria Kecskemeti
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

6.  The antidepressant fluoxetine mobilizes vesicles to the recycling pool of rat hippocampal synapses during high activity.

Authors:  Jasmin Jung; Kristina Loy; Eva-Maria Schilling; Mareike Röther; Jan M Brauner; Tobias Huth; Ursula Schlötzer-Schrehardt; Christian Alzheimer; Johannes Kornhuber; Oliver Welzel; Teja W Groemer
Journal:  Mol Neurobiol       Date:  2013-11-05       Impact factor: 5.590

7.  Basic presynaptic functions in hippocampal neurons are not affected by acute or chronic lithium treatment.

Authors:  Katharina Lueke; Tobias Kaiser; Alexei Svetlitchny; Oliver Welzel; Eva M Wenzel; Shiva Tyagarajan; Johannes Kornhuber; Teja W Groemer
Journal:  J Neural Transm (Vienna)       Date:  2013-09-15       Impact factor: 3.575

Review 8.  The Neurobiology of Depression: an Integrated Overview from Biological Theories to Clinical Evidence.

Authors:  F Ferrari; R F Villa
Journal:  Mol Neurobiol       Date:  2016-08-10       Impact factor: 5.590

9.  Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo.

Authors:  R Kaddurah-Daouk; M B Bogdanov; W R Wikoff; H Zhu; S H Boyle; E Churchill; Z Wang; A J Rush; R R Krishnan; E Pickering; M Delnomdedieu; O Fiehn
Journal:  Transl Psychiatry       Date:  2013-01-22       Impact factor: 6.222

10.  Candidate genes for antidepressant response to selective serotonin reuptake inhibitors.

Authors:  Francis E Lotrich; Bruce G Pollock
Journal:  Neuropsychiatr Dis Treat       Date:  2005-03       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.